X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA NOVARTIS PLETHICO PHARMA/
NOVARTIS
 
P/E (TTM) x -1.1 328.0 - View Chart
P/BV x 0.0 36.4 0.0% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 PLETHICO PHARMA   NOVARTIS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
NOVARTIS
Mar-18
PLETHICO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs395758 52.1%   
Low Rs31579 5.4%   
Sales per share (Unadj.) Rs604.4228.4 264.6%  
Earnings per share (Unadj.) Rs32.531.7 102.3%  
Cash flow per share (Unadj.) Rs51.332.8 156.7%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs473.6297.1 159.4%  
Shares outstanding (eoy) m34.0824.69 138.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.9 12.0%   
Avg P/E ratio x6.621.1 31.1%  
P/CF ratio (eoy) x4.220.4 20.3%  
Price / Book Value ratio x0.52.2 20.0%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m7,26216,505 44.0%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m1,5961,445 110.4%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m20,5985,639 365.3%  
Other income Rs m3861,718 22.5%   
Total revenues Rs m20,9847,357 285.2%   
Gross profit Rs m2,818-63 -4,508.3%  
Depreciation Rs m64225 2,538.7%   
Interest Rs m1,59355 2,881.0%   
Profit before tax Rs m9691,575 61.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138792 -17.5%   
Profit after tax Rs m1,107784 141.3%  
Gross profit margin %13.7-1.1 -1,234.2%  
Effective tax rate %-14.350.3 -28.4%   
Net profit margin %5.413.9 38.7%  
BALANCE SHEET DATA
Current assets Rs m18,8779,522 198.3%   
Current liabilities Rs m11,8963,296 360.9%   
Net working cap to sales %33.9110.4 30.7%  
Current ratio x1.62.9 54.9%  
Inventory Days Days3637 98.1%  
Debtors Days Days19828 696.0%  
Net fixed assets Rs m9,86146 21,435.9%   
Share capital Rs m341123 276.1%   
"Free" reserves Rs m12,3317,213 170.9%   
Net worth Rs m16,1397,336 220.0%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14611,105 298.5%  
Interest coverage x1.629.5 5.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.5 122.4%   
Return on assets %8.17.6 107.8%  
Return on equity %6.910.7 64.2%  
Return on capital %12.322.2 55.3%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40261 7,264.7%   
Fx outflow Rs m3,1843,630 87.7%   
Net fx Rs m1,219-3,570 -34.1%   
CASH FLOW
From Operations Rs m2,4371,610 151.4%  
From Investments Rs m-6,265687 -911.9%  
From Financial Activity Rs m2,490-2,677 -93.0%  
Net Cashflow Rs m-1,337-380 352.3%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 2.0 215.0%  
FIIs % 5.5 1.6 343.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.5 34.9%  
Shareholders   10,665 41,647 25.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - LUPIN LTD COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS